Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03529708
Other study ID # 4760
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 1, 2018
Est. completion date December 1, 2020

Study information

Verified date January 2020
Source Juravinski Cancer Center
Contact Elysia K Donovan, MD,FRCPC
Phone 9053879495
Email donovane@hhsc.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Spinal cord compression (SCC) is a devastating complication of advanced malignancy, and can cause significant deterioration in function and quality of life (QoL). The goal of treatment is to improve functional status and symptoms, but the optimal treatment regimen for these patients has not been thoroughly established. Many patients with SCC present with uncontrolled systemic disease and poor performance status, and are not eligible for standard surgical resection. They are generally treated with 3D conformal palliative RT (3DCRT) alone, however recent trials suggest that less than 70% of patients are ambulatory, that the re-establishment of ambulation in non-ambulatory patients is poor, and the duration of improvement is guarded with radiotherapy alone.

Recently, stereotactic body radiotherapy (SBRT) used alone or after previous radiotherapy to treat spinal metastasis has demonstrated superior results in pain control, tumour response and durability. SBRT requires time for careful planning, and many patients with neurologic symptoms must be treated immediately to prevent progression. Therefore the role of SBRT is still unclear in this patient population, although it seems to be a potential alternative to surgical decompression in patient not suitable for surgery. The investigators propose a feasibility study to investigate the potential benefits of dose escalation with a sequential SBRT boost to urgent 3D CRT in the setting of SCC. This regimen will allow inoperable patients to receive urgent 3DCRT while simultaneously creating the opportunity for superior outcomes with SBRT. The investigators also aim to characterize the effect on motor function and ambulation, pain and QoL. This study could stimulate further multi-center randomized trials in this area, improve motor function and patient-reported QoL, and contribute to improving oncology care in Canada in a meaningful way.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date December 1, 2020
Est. primary completion date June 1, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Diagnosis of metastatic malignancy (radiologic or pathologic)

2. Evidence of disease in vertebral body with epidural component such that Bilsky radiologic score is 1c-2 on MRI (abuts spinal cord without cord compression (1c), or spinal cord compression but with visible CSF (2)

3. Motor function (MF) of 3 or greater

Exclusion Criteria:

1. Surgical candidate

2. Instability of vertebral bodies with or without bony retropulsion requiring surgical intervention or hardware placement

3. Previous radiotherapy course to same region of spine with overlapping fields (prior to phase I course) at discretion of treating radiation oncologist

4. No CT or MRI within previous 3 months

5. Life expectancy estimated <3 months

6. Performance status KPS<40

7. On active chemotherapy or targeted therapy or immunotherapy (must be stopped for at least one week prior to and following)

8. Pregnant or lactating

9. Contraindications to radiotherapy (eg. active autoimmune disease requiring medication)

10. Inability to lie flat comfortably for at least 20 minutes

11. Age < 18

Study Design


Intervention

Radiation:
3D CRT plus SBRT boost
Patients will receive urgent standard 3D conformal radiotherapy (3D CRT) of plus stereotactic boost to tumor causing spinal cord compression (SCC). Initial dose for 3D CRT will be either 8Gy in 1 fraction or 20Gy in 5 fractions, with SBRT boost dose15Gy in 2 fractions of 12Gy in 2 fractions (depending on 8Gy/1 or 20Gy/5 initial RT dose respectively), delivered within three weeks of first treatment.

Locations

Country Name City State
Canada Juravinski Cancer Center Hamilton Ontario

Sponsors (3)

Lead Sponsor Collaborator
Juravinski Cancer Center Hamilton Health Sciences Corporation, Juravinski Cancer Centre Foundation

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility of accrual Success determined by accrual of 30 patients with SBRT boost is planned and delivered to 80% of these up to 12 months
Secondary Motor Function Description: Motor strength evaluated by 8 point scale (0= Complete paraplegia, 1= Palpable or visible muscle contractions, 2= Active movement of the leg without gravity, 3= Active movement of the leg against gravity, 4= Active movement againt mild resistance, 5= Active movement against intermediate resistance, 6= Active movement against strong resistance, 7= Normal strength) 4 weeks (primary), 12 weeks, 6 months
Secondary Overall Quality of Life (QoL) Change in total QoL score over time per European Organization for Research and Treatment of Cancer Quality of Life Questionnaire core 30 (EORTC QLQ-c30) 4 weeks, 12 weeks, 6 months
Secondary Pain Response Change in level of pain over time on 10 point scale with 0 meaning no pain and 10 meaning severe pain (patient-reported) 4 weeks, 12 weeks, 6 months
Secondary Local Control Assessment of tumor volume (maximum size in 3 dimension) by Magnetic Resonance Imaging (MRI) 12 weeks, 6 months
Secondary Toxicity Treatment-related toxicity graded by Common Terminology for Adverse Events (CTCAE 4.03) 4 weeks, 12 weeks, 6 months
Secondary Overall Survival Survival time from first radiotherapy treatment (3D CRT) in days 4 weeks, 12 weeks, 6 months
Secondary Bone metastasis- specific Quality of Life Change in total QoL score over time per European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Bone Metastasis-22 (EORTC QLQ BM-22) 4 weeks, 12 weeks, 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05023772 - Laser Interstitial Thermal Ablation and Stereotactic Radiosurgery for Patients With Spine Metastases N/A
Not yet recruiting NCT06077071 - MRIdian "RADAR" Trial N/A
Not yet recruiting NCT02934594 - Metastatic Spinal Cord Compression (MSCC): Treatment Timing and Survival Rate N/A
Completed NCT02926391 - UNiD 3D VBR Register
Recruiting NCT01826058 - Spine Stereotactic Body Radiation Therapy for Metastatic Epidural Spinal Cord Compression Phase 2
Completed NCT00974168 - Spinal Cord Compression Re-Treat Study Phase 2
Completed NCT00727584 - Radiation Therapy in Treating Patients With Metastatic Spinal Cord Compression N/A
Completed NCT00280306 - White Matter Fiber Tracking and Assessment of White Matter Integrity in the Cervical Spinal Cord N/A
Terminated NCT00215527 - Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis (MPS) I Phase 1
Completed NCT02527304 - Adaptive Staged Stereotactic Body Radiation Therapy in Treating Patients With Spinal Metastases That Cannot Be Removed by Surgery N/A
Terminated NCT01407341 - Beta-Tricalcium Phosphate Bone Graft in Treating Patients Undergoing Surgery For Metastatic Spine Cancer Phase 1
Recruiting NCT05910593 - Establishing the Validity and Reliability of a Dexterity Assessment Tool
Terminated NCT02167633 - Stereotactic Radiosurgery in Metastatic Spinal Cord Compression N/A
Enrolling by invitation NCT03225625 - Stem Cell Spinal Cord Injury Exoskeleton and Virtual Reality Treatment Study N/A
Completed NCT04925882 - Erector Spinae Plane Block in Lumbar Release Surgery N/A
Completed NCT02006901 - Comparative Effectiveness of Microdecompression and Laminectomy for Central Lumbar Spinal Stenosis N/A
Terminated NCT00786968 - Extension Study of Intrathecal Enzyme Replacement Therapy for MPS I Phase 1
Completed NCT00968643 - Spinal Cord Compression. ICORG 05-03, V6 Phase 3
Recruiting NCT05530798 - CEUS For Intraoperative Spinal Cord Injury N/A
Completed NCT02713269 - Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord Phase 2